229 related articles for article (PubMed ID: 36206989)
1. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
3. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
Das A; Durrant D; Salloum FN; Xi L; Kukreja RC
Pharmacol Ther; 2015 Mar; 147():12-21. PubMed ID: 25444755
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Multifaceted Potential of Sildenafil in Medicine.
Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
[TBL] [Abstract][Full Text] [Related]
6. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
Poitras EL; Gust SL; Kerr PM; Plane F
Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
[TBL] [Abstract][Full Text] [Related]
8. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.
González-Corrochano R; La Fuente J; Cuevas P; Fernández A; Chen M; Sáenz de Tejada I; Angulo J
Br J Pharmacol; 2013 May; 169(2):449-61. PubMed ID: 23441682
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
10. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
12. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients.
Kniotek M; Boguska A
J Immunol Res; 2017; 2017():4541958. PubMed ID: 28316997
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
15. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Zhang WH; Zhang XH
Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
[TBL] [Abstract][Full Text] [Related]
16. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
17. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Cyclic GMP Export by Multidrug Resistance Protein 4: A New Strategy to Treat Erectile Dysfunction?
Boydens C; Pauwels B; Vanden Daele L; Van de Voorde J
J Sex Med; 2017 Apr; 14(4):502-509. PubMed ID: 28258955
[TBL] [Abstract][Full Text] [Related]
19. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
